BlackRock Health Sciences Term Trust (BMEZ) to Issue Monthly Dividend of $0.18 on November 29th

Posted by Chris Copeland on Nov 13th, 2024

BlackRock Health Sciences Term Trust (NYSE:BMEZ – Get Free Report) announced a monthly dividend on Friday, November 1st,NASDAQ Dividends reports. Stockholders of record on Friday, November 15th will be paid a dividend of 0.1769 per share on Friday, November 29th. This represents a $2.12 annualized dividend and a dividend yield of 13.53%. The ex-dividend date is Friday, November 15th.

BlackRock Health Sciences Term Trust has increased its dividend by an average of 20.7% annually over the last three years.

BlackRock Health Sciences Term Trust Stock Down 0.9 %

Shares of NYSE:BMEZ traded down 0.15 during trading on Wednesday, hitting 15.69. 205,267 shares of the company were exchanged, compared to its average volume of 264,339. BlackRock Health Sciences Term Trust has a 12-month low of 13.41 and a 12-month high of 16.59. The firm’s 50 day moving average price is 15.80 and its 200-day moving average price is 15.56.

Insider Activity

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. bought 29,795 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were acquired at an average cost of 15.81 per share, with a total value of 471,058.95. Following the acquisition, the insider now directly owns 20,750,913 shares of the company’s stock, valued at 328,071,934.53. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have acquired 99,630 shares of company stock valued at $1,585,113 in the last ninety days.

BlackRock Health Sciences Term Trust Company Profile

(Get Free Report)

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.